Oxymetazoline

Summary

Oxymetazoline (CHEMBL762) is an approved small-molecule α-adrenergic agonist (ATC D11AX27) targeting ADRA1A, ADRA1B, and ADRA1D; indicated across 10 conditions including eye allergy and rosacea.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D11AX27 (+3 more)
• Targets: 9 (ADRA1A, ADRA1B, ADRA1D…)
• Indications: 10 conditions
• Clinical trials: 38
• Chemistry: 260.37 Da · C16H24N2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL762
Name	Oxymetazoline
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4636
ChEBI	CHEBI:7862
ATC	D11AX27, R01AA05, S01GA04, R01AB07
Molecular formula	C16H24N2O
Molecular weight	260.37
InChIKey	WYWIFABBXFUGLM-UHFFFAOYSA-N

SMILES: CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C

IUPAC name: 6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol

ChEBI definition: A member of the class of phenols that is 2,4-dimethylphenol which is substituted at positions 3 and 6 by 4,5-dihydro-1H-imidazol-2-ylmethyl and tert-butyl groups, respectively. A direct-acting sympathomimetic with marked α-adrenergic activity, it is a vasoconstrictor that is used (generally as the hydrochloride salt) to relieve nasal congestion.

Pharmacological roles (ChEBI): α-adrenergic agonist, sympathomimetic agent, nasal decongestant, vasoconstrictor agent.

Also known as: Afrin, Nasacon, Operil, Oximetazolina, Oxymetazoline, oxymetazoline, SID11111570, SID11111571, SID11113337, SID26751491, SID26751492, SID90341671

Parent form; salt/anhydrous children: CHEMBL1200791

Patent coverage: 3,595 distinct patent families (13,685 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 13,682 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ADRA1A	α1A-adrenoceptor	Full agonist	9.3		P35348
ADRA1B	α1B-adrenoceptor	Full agonist	6.5	0%	P35368
ADRA1D	α1D-adrenoceptor	Partial agonist	6.4	0.2%	P25100
ADRA2A	α2A-adrenoceptor	Partial agonist	8.4	0.1%	P08913
ADRA2B	α2B-adrenoceptor	Agonist	6.2	0.2%	P18089
ADRA2C	α2C-adrenoceptor	Agonist	6.7	0%	P18825
HTR1B	5-HT1B receptor	Full agonist	9.5	0.2%	P28222
HTR1D	5-HT1D receptor	Partial agonist	9.4	0%	P28221
HTR2C	5-HT2C receptor	Full agonist	6.8	0%	P28335

Broader ChEMBL bioactivity targets: 45 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Prelamin-A/C, Muscarinic acetylcholine receptor M4, 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, 5-hydroxytryptamine receptor 1B, Adrenergic receptor alpha-1, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Thyrotropin receptor.

Bioactivity

ChEMBL activities: 103 potent at pChembl ≥ 5 of 119 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRA2A	9.54	Ki	0.29	nM	CHEMBL_ACT_13876519
HTR1B	9.52	Ki	0.3	nM	CHEMBL_ACT_443019
HTR1D	9.4	Ki	0.4	nM	CHEMBL_ACT_443020
P28564	9.04	Ki	0.91	nM	CHEMBL_ACT_7716954
ADRA2C	9	Ki	1	nM	CHEMBL_ACT_13876517
P19328	8.82	Ki	1.5	nM	CHEMBL_ACT_18393146
Q28838	8.82	Ki	1.5	nM	CHEMBL_ACT_344863
P15823	8.72	Ki	1.9	nM	CHEMBL_ACT_14624390
ADRA1A	8.72	AC50	1.9	nM	CHEMBL_ACT_25229490
P19328	8.72	Ki	1.9	nM	CHEMBL_ACT_527493
P28564	8.7	IC50	2	nM	CHEMBL_ACT_7716953
ADRA2A	8.66	Ki	2.2	nM	CHEMBL_ACT_344841
ADRA2A	8.64	Ki	2.29	nM	CHEMBL_ACT_13876469
ADRA2A	8.52	Ki	3	nM	CHEMBL_ACT_344857
P19327	8.49	Ki	3.21	nM	CHEMBL_ACT_7716952
ADRA2A	8.48	EC50	3.31	nM	CHEMBL_ACT_550461
ADRA2A	8.46	Ki	3.5	nM	CHEMBL_ACT_344840
ADRA2C	8.3	Ki	5.01	nM	CHEMBL_ACT_13876483
P19328	8.3	IC50	5	nM	CHEMBL_ACT_145965
P19327	8.25	IC50	5.61	nM	CHEMBL_ACT_7716951
NISCH	8.21	Ki	6.19	nM	CHEMBL_ACT_2564080
NISCH	8.21	Ki	6.2	nM	CHEMBL_ACT_2564081
P43140	8.19	Ki	6.46	nM	CHEMBL_ACT_136036
P19328	8.1	Ki	8	nM	CHEMBL_ACT_344861
ADRA2A	8.06	Ki	8.64	nM	CHEMBL_ACT_7714757
HTR1A	8.03	AC50	9.4	nM	CHEMBL_ACT_25216618
ADRA2A	8.01	AC50	9.8	nM	CHEMBL_ACT_25220681
P19328	8	Ki	10	nM	CHEMBL_ACT_344860
ADRA2A	7.98	Ki	10.5	nM	CHEMBL_ACT_344844
P18130	7.88	Ki	13.18	nM	CHEMBL_ACT_136037

Target pathways

Aggregated over 9 target gene(s): ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C.

Top Reactome pathways

22 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	9	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
Signaling by GPCR	9	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
Class A/1 (Rhodopsin-like receptors)	9	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
Amine ligand-binding receptors	9	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
GPCR downstream signalling	9	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
GPCR ligand binding	9	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
Adrenoceptors	6	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
G alpha (i) signalling events	5	ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D
G alpha (q) signalling events	4	ADRA1A, ADRA1B, ADRA1D, HTR2C
Hemostasis	3	ADRA2A, ADRA2B, ADRA2C
Serotonin receptors	3	HTR1B, HTR1D, HTR2C
Adrenaline signalling through Alpha-2 adrenergic receptor	3	ADRA2A, ADRA2B, ADRA2C
G alpha (12/13) signalling events	3	ADRA1A, ADRA1B, ADRA1D
G alpha (z) signalling events	3	ADRA2A, ADRA2B, ADRA2C
Platelet activation, signaling and aggregation	3	ADRA2A, ADRA2B, ADRA2C
Platelet Aggregation (Plug Formation)	3	ADRA2A, ADRA2B, ADRA2C
Metabolism	2	ADRA2A, ADRA2C
Integration of energy metabolism	2	ADRA2A, ADRA2C
Metabolism of proteins	2	ADRA2A, ADRA2C
Adrenaline,noradrenaline inhibits insulin secretion	2	ADRA2A, ADRA2C
Regulation of insulin secretion	2	ADRA2A, ADRA2C
Surfactant metabolism	2	ADRA2A, ADRA2C

Dominant GO biological processes

GO term	Targets
signal transduction	9
G protein-coupled receptor signaling pathway	9
positive regulation of MAPK cascade	6
adrenergic receptor signaling pathway	6
cell-cell signaling	5
regulation of vasoconstriction	5
phospholipase C-activating G protein-coupled receptor signaling pathway	4
adenylate cyclase-activating adrenergic receptor signaling pathway	4
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	4
positive regulation of cytosolic calcium ion concentration	3
neuron-glial cell signaling	3
epidermal growth factor receptor signaling pathway	3
negative regulation of norepinephrine secretion	3
platelet activation	3
negative regulation of epinephrine secretion	3

Indications & clinical

Indications

10 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye allergy	4	MONDO:0005551	EFO:0005751
rosacea	3	MONDO:0006604	EFO:1000760
seasonal allergic rhinitis	2	MONDO:0005324	EFO:0003956
allergic rhinitis	2	MONDO:0011786	EFO:0005854
orthostatic hypotension	1	MONDO:0005469	EFO:0005252
common cold	1	MONDO:0005709	EFO:0007214
presbyopia	1	MONDO:0001330	MONDO:0001330

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 38.

Phase distribution

Phase	Trials
PHASE4	12
PHASE1	10
PHASE3	6
PHASE2	5
Not specified	4
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02630121	PHASE4	RECRUITING	Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
NCT07390578	PHASE4	NOT_YET_RECRUITING	Upneeq vs. Lumify Ptosis
NCT00487032	PHASE4	COMPLETED	Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation
NCT00584987	PHASE4	COMPLETED	Intranasal Steroids and Oxymetazoline in Allergic Rhinitis
NCT00846326	PHASE4	WITHDRAWN	Preventing Tolerance to Oxymetazoline in Allergic Rhinitis
NCT01847131	PHASE4	COMPLETED	Effectiveness of Oxymetazoline Added on Nasal Steroid in Rhinitis With Persistent Nasal Obstruction
NCT02559440	PHASE4	COMPLETED	Mometasone Furoate and Oxymetazoline in the Treatment of Adenoid Hypertrophy
NCT03228914	PHASE4	COMPLETED	Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery
NCT03380390	PHASE4	COMPLETED	Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea
NCT04153188	PHASE4	COMPLETED	Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea
NCT04831047	PHASE4	COMPLETED	The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance
NCT07593898	PHASE4	COMPLETED	Oxymetazoline Bridge Therapy With Intranasal Corticosteroids in Pediatric Allergic Rhinitis
NCT02095158	PHASE3	COMPLETED	A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea
NCT02132117	PHASE3	COMPLETED	Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea
NCT02601235	PHASE3	COMPLETED	Efficacy and Safety of Pediatric Drugs in Nasal Congestion
NCT03352323	PHASE3	COMPLETED	An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
NCT03954444	PHASE3	COMPLETED	A Clinical Endpoint Bioequivalence Study of Oxymetazoline Hydrochloride Cream
NCT05945615	PHASE3	COMPLETED	Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis
NCT07582328	PHASE2	RECRUITING	A Study to Learn More About How Well Oxymetazoline HCl 0.05% Nasal Gel Works and How Safe It Is in Healthy Adults
NCT01275105	PHASE2	COMPLETED	A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)
NCT01986582	PHASE2	COMPLETED	NoAL (HPMC) in Combination With Oxymetazoline in Patients With Allergic Rhinitis
NCT02062996	PHASE2	WITHDRAWN	Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption
NCT07168148	PHASE2	TERMINATED	Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants
NCT00223691	PHASE1	COMPLETED	Treatment of Orthostatic Hypotension in Autonomic Failure
NCT01363089	PHASE1	COMPLETED	Study to Assess the PK of Ketorolac Tromethamine Intranasal and to Assess the Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine
NCT01365650	PHASE1	COMPLETED	Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of Oxymetazoline Hydrochloride and Fluticasone Propionate on the Absorption and Tolerability of Intranasal Ketorolac Tromethamine in Participants With Allergic Rhinitis
NCT01925729	PHASE1	COMPLETED	TransMEM Gas Exchange – Project 1, Aim 2
NCT02154334	PHASE1	COMPLETED	Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine
NCT02778100	PHASE1	COMPLETED	A Study of Nasal Glucagon in Participants With a Common Cold
NCT03529487	PHASE1	UNKNOWN	Intra-anal Oxymetazoline in Healthy Adult Volunteers
NCT05001243	PHASE1	UNKNOWN	Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients
NCT05006911	PHASE1	UNKNOWN	Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms
NCT05148689	PHASE1	COMPLETED	A Study Comparing Oxymetazoline 1% Cream to RHOFADE
NCT06874244	EARLY_PHASE1	COMPLETED	Clinical Evaluation of no Needle Dental Anesthesia Compared to Syringe Anesthesia Delivery
NCT00584662	Not specified	TERMINATED	Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion
NCT02285634	Not specified	COMPLETED	The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.
NCT02453841	Not specified	COMPLETED	Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption
NCT06480071	Not specified	COMPLETED	The Role of Nasal Breathing for Perfomance in Elite Athletes.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

840 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
AZELASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
CARIPRAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
NEFAZODONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
RISPERIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
XYLOMETAZOLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR2C
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR2C
TEGASEROD	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1D, HTR2C
ERGOTAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
SERTINDOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR2C
SILODOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D
VILAZODONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D
LATREPIRDINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1D, HTR2C
YOHIMBINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D
NIGULDIPINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR2C
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C
ASENAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
CISAPRIDE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
CLONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
DOXAZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
EBASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
KETOTIFEN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR2C
MIANSERIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1D, HTR2C
MOXISYLYTE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
PHENTOLAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
PRAZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1D
QUETIAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
VERAPAMIL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
PIZOTYLINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
RITANSERIN	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR2C
SPIRAMIDE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1D
ZOTEPINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B
TAMSULOSIN	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
ALFUZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
AMLODIPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2C, HTR2C
AMOXAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
APOMORPHINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
APRACLONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
BENZTROPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
BRIMONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
CARVEDILOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
CLEMASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
DEXMEDETOMIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
DOMPERIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
DOXEPIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C
EPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR2C